bioRxiv ScienceSearch

Biology subjects

Choi, S. W.

Publications and source records attributed to Choi, S. W..

2 recordsLinked to original sources

A guide to performing Polygenic Risk Score analyses

The application of polygenic risk scores (PRS) has become routine across genetic research. Among a range of applications, PRS are exploited to assess shared aetiology between phenotypes, to evaluate the predictive power of genetic data for use in clinical settings, and as part of experimental studies in which, for example, experiments are performed on individuals, or their biological samples (eg. tissues, cells), at the tails of the PRS distribution and contrasted. As GWAS sample sizes increase and PRS become more powerful, they are set to play a key role in personalised medicine. However, despite the growing application and importance of PRS, there are limited guidelines for performing PRS analyses, which can lead to inconsistency between studies and misinterpretation of results. Here we provide detailed guidelines for performing polygenic risk score analyses relevant to different methods for their calculation, outlining standard quality control steps and offering recommendations for best-practice. We also discuss different methods for the calculation of PRS, common misconceptions regarding the interpretation of results and future challenges.

genomics

Polygenic scores without external summary statistics

Polygenic scores (PGS) are estimated scores representing the genetic tendency of an individual for a disease or trait and have become an indispensible tool in a variety of analyses. Typically they are linear combination of the genotypes of a large number of SNPs, with the weights calculated from an external source, such as summary statistics from large meta-analyses. Recently cohorts with genetic data have become very large, such that it would be a waste if the raw data were not made use of in constructing PGS. Making use of raw data in calculating PGS, however, presents us with problems of overfitting. Here we discuss the essence of overfitting as applied in PGS calculations and highlight the difference between overfitting due to the overlap between the target and the discovery data (OTD), and overfitting due to the overlap between the target the the validation data (OTV). We propose two methods -- cross prediction and split validation -- to overcome OTD and OTV respectively. Using these two methods, PGS can be calculated using raw data without overfitting. We show that PGSs thus calculated have better predictive power than those using summary statistics alone for six phenotypes in the UK Biobank data.

genomics